Medicenna Therapeutics shareholders approved all proposals at the company’s October 1, 2026 annual general and special meeting, including the election of four directors, the reappointment of MNP LLP as auditor and a potential share consolidation. Each director received more than 97% of votes cast by shareholders present or represented by proxy. The approved consolidation would exchange one post-consolidation common share for every 2 to 20 pre-consolidation shares, with the final ratio and decision to proceed left to the board. Medicenna said the measure could support compliance with minimum bid-price requirements for a major U.S. stock exchange and potentially broaden access to institutional investors, but it would not guarantee a listing. The company is a clinical-stage immunotherapy developer focused on engineered cytokine therapies and Superkines (engineered immune-signaling proteins) for cancer and autoimmune diseases.